KabaFusion Selects CareCloud to Build First-of-Its-Kind Platform for Home Infusion and Specialty Pharmacy
Rhea-AI Summary
CareCloud (Nasdaq: CCLD) and home infusion provider KabaFusion have formed a partnership to build LailaCare, an artificial intelligence-powered platform for home infusion and specialty pharmacy operations. CareCloud will design and develop the fully integrated application, while ownership of the platform will reside with KabaFusion.
LailaCare is intended to consolidate referral intake, eligibility and authorization, patient engagement, and revenue cycle management into a single workflow. According to the companies, AI will support end-to-end processes such as routing referrals, assisting with eligibility checks, and scrubbing claims to help prevent denials, while keeping KabaFusion staff in control of clinical and exception decisions.
Positive
- Strategic AI partnership with major provider KabaFusion selects CareCloud to build LailaCare for home infusion and specialty pharmacy.
- End-to-end workflow platform LailaCare is designed to unify intake, eligibility, engagement, and revenue cycle into one system.
- AI-centric product development Artificial intelligence is positioned at the core of LailaCare’s home infusion pharmacy operations workflow.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 06 | Q2 earnings report | Negative | -8.7% | Profitability metrics declined despite revenue growth, and shares fell 8.66% over 24 hours. |
| Jul 16 | Earnings date notice | Neutral | -0.6% | Results-date notice preceded a 0.64% 24-hour decline without operating results. |
| Jun 08 | Medicare appeal outcome | Positive | +0.8% | Medicare appeal reversed more than $1 million in alleged overpayments. |
| Jun 05 | Shareholder approval | Positive | -2.1% | Shareholders approved board, compensation, incentive-plan, and auditor proposals; shares declined 2.08%. |
| May 26 | Compliance acquisition | Positive | -3.1% | Acquisition added compliance services and recurring-revenue opportunity; shares declined 3.07%. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history showed predominantly negative reactions, including declines after earnings, governance, and acquisition announcements.
Key Terms
home infusion therapy medical
specialty pharmacy medical
revenue cycle management financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
KabaFusion partners with CareCloud to develop a fully integrated application, powered by artificial intelligence, designed for the home infusion workflow
Somerset, NJ and Lexington, MA, Aug. 18, 2026 (GLOBE NEWSWIRE) -- KabaFusion, one of the nation's largest providers of home infusion therapy, and CareCloud, Inc. (Nasdaq: CCLD) (“CareCloud” or the “Company”), a leader in healthcare technology, today announced a partnership to build LailaCare, a platform powered by artificial intelligence and designed to support and modernize KabaFusion's operations as a home infusion and specialty pharmacy provider. CareCloud will design and develop the platform, which will be owned by KabaFusion.
LailaCare will unify workflows including referral intake, eligibility and authorization, patient engagement, and revenue cycle management, into a single, integrated platform. The project is designed to reduce administrative burden and accelerate patient onboarding, while giving patients modern access to their own care journey.
Artificial intelligence will be at the core of the platform. It is designed to power LailaCare's workflow end-to-end within home infusion pharmacy operations, identifying and routing referrals at intake, supporting eligibility and authorization, and scrubbing claims to help prevent denials in the revenue cycle, while keeping KabaFusion's trained staff in control of clinical and exception decisions.
"KabaFusion has spent years building a reputation for high quality, patient-centered infusion care, and we are always looking for ways to strengthen that foundation," said Dr. Sohail Masood, Chairman and CEO of KabaFusion. "LailaCare is a natural next step for us. It will give our team the tools to work more efficiently and give our patients a more connected experience, while reinforcing the standard of care that has defined KabaFusion from the start."
"CareCloud has spent 25 years building healthcare platforms at scale, and AI is now at the center of how we build," said Stephen Snyder, Chief Executive Officer of CareCloud. "LailaCare will pair KabaFusion's deep operational expertise in home infusion with CareCloud's technology and our AI Center of Excellence, exactly the kind of platform we are investing in, one designed to deliver measurable value to customers and to reflect the growing role of AI across our business."
About CareCloud
CareCloud brings disciplined innovation to the business of healthcare. Our suite of AI and technology-enabled solutions helps clients increase financial and operational performance, streamline clinical workflows and improve the patient experience. More than 40,000 providers count on CareCloud to help them improve patient care, while reducing administrative burdens and operating costs. Learn more about our products and services, including revenue cycle management (RCM), practice management (PM), electronic health records (EHR), business intelligence, patient experience management (PXM) and digital health, at carecloud.com.
Follow CareCloud on LinkedIn, X and Facebook.
For additional information, please visit our website at carecloud.com. To listen to video presentations by CareCloud’s management team, read recent press releases and view the latest investor presentation, please visit ir.carecloud.com.
About KabaFusion
KabaFusion is a national provider of chronic and acute infusion therapies. KabaFusion serves patients in 49 states through its nationwide network of home infusion pharmacies, ambulatory infusion suites, and home health agencies. KabaFusion was founded in 2010 by Chief Executive Officer Dr. Sohail Masood, a pioneer in patient-focused infusion therapies with more than 30 years of clinical experience. KabaFusion is dedicated to working proactively with patients, healthcare practitioners, and payors to provide comprehensive support before, during and after treatment. For more information, visit Kabafusion.com.
Forward Looking Statements
This press release contains various forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements relate to anticipated future events, future results of operations or future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “might,” “will,” “shall,” “should,” “could,” “intends,” “expects,” “plans,” “goals,” “projects,” “anticipates,” “believes,” “seeks,” “estimates,” “forecasts,” “predicts,” “possible,” “potential,” “target,” or “continue” or the negative of these terms or other comparable terminology.
Our operations involve risks and uncertainties, many of which are outside our control and any one of which, or a combination of which, could materially affect our results of operations and whether the forward-looking statements ultimately prove to be correct. Forward-looking statements in this press release include, without limitation, statements reflecting management's expectations for future financial performance and operating expenditures, expected growth, profitability and business outlook, the impact of pandemics on our financial performance and business activities and the expected results from the integration of our acquisitions.
These forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are only predictions, are uncertain and involve substantial known and unknown risks, uncertainties and other factors which may cause our (or our industry’s) actual results, levels of activity or performance to be materially different from any future results, levels of activity or performance expressed or implied by these forward-looking statements. New risks and uncertainties emerge from time to time and it is not possible for us to predict all of the risks and uncertainties that could have an impact on the forward-looking statements, including without limitation, risks and uncertainties relating to the Company’s ability to manage growth, migrate newly acquired customers and retain new and existing customers, maintain cost-effective global operations, increase operational efficiency and reduce operating costs, predict and properly adjust to changes in reimbursement and other industry regulations and trends, retain the services of key personnel, develop new technologies, upgrade and adapt legacy and acquired technologies to work with evolving industry standards, compete with other companies’ products and services competitive with ours, manage and keep our information systems secure and other important risks and uncertainties referenced and discussed under the heading titled “Risk Factors” in the Company’s filings with the Securities and Exchange Commission.
The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not assume any obligations to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.
Media Contacts for KabaFusion
Kelly Aldridge
SVP of Sales and Marketing
kaldridge@kabafusion.com
Media Contacts for CareCloud
Company Contact:
Norman Roth
Interim Chief Financial Officer and Corporate Controller
CareCloud, Inc.
nroth@carecloud.com
Investor Contact:
Stephen Snyder
Chief Executive Officer
CareCloud, Inc.
ir@carecloud.com
